Intervention: Disulfiram
Trial phase: Phase 1 | Phase 2
ATC code: N07BB01 | P03AA04 | P03AA54
SMILES: CCN(CC)C(=S)SSC(=S)N(CC)CC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: 500mg disulfiram by mouth per day for 3 days

Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
Eligibility criteria:
Inclusion Criteria:

HIV-1 infection
Age 18 or older
HIV plasma viral load <50 copies/ml for at least 3 years with at least one measurement per year and most recent viral load within 3 months of screening.
Receiving combination antiretroviral therapy (at least 3 agents); subjects must be on a efavirenz-based or a ritonavir-based regimen
Two CD4+ T cell counts greater than 350 cell/µl in the six months prior to screening
Willing to abstain from any alcohol one day before, during the three day period in which disulfiram will be administered and the two week period immediately after disulfiram administration

Exclusion Criteria:

Current alcohol use disorder or hazardous alcohol use
Current use of any drug formulation that contains alcohol or that might contain alcohol, including the gelatin capsule and liquid formulations of ritonavir, ritonavir/lopinavir, amprenavir and fosamprenavir.
Current use of tipranavir or maraviroc.
Current use of zidovudine, stavudine or didanosine (as disulfiram potentially has potent irreversible inhibitory effects on mitochondrial metabolism and hence could exacerbate the toxicity of these drugs).
Concurrent use of rivaroxaban ( a CYP3A metabolized medication) as the cytochrome P450 inhibitory effects of disulfiram on rivaroxaban are unknown.
Current use of warfarin
Patients who are intending to modify antiretroviral therapy in the next 2 weeks for any reason.
Serious illness requiring hospitalization or parental antibiotics within preceding 3 months
A screening hemoglobin below 12.5 g/dL
A screening TSH consistent with Hypothyroidism
Significant renal disease or acute nephritis
Significant myocardial disease or diagnosed coronary artery disease
Significant respiratory disease
History of psychosis, seizure disorder, abnormal electroencephalogram or brain damage with significant persisting neurological deficit.
Clinically active hepatitis as evidenced by clinical jaundice or Grade 2 or higher liver function test abnormalities.
Hepatic cirrhosis or decompensated chronic liver disease.
Diabetes or current hypothyroidism.
Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drug in past 16 weeks.
Recent exposure (within the preceding 8 weeks) to any vaccine.
Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.
Significant substance use, which in the opinion of the investigator, is likely to interfere with the conduct of the study.
Prior or current use of disulfiram, vorinostat or other experimental agent used with the intent to perturb the HIV-1 viral reservoir
Current use of an antiretroviral regimen which does not include either efavirenz or a protease inhibitor